Vision
Affitech A/S is building an international biopharmaceutical company focused on developing human antibody therapeutics derived from the Company’s human antibody platform bringing new treatment options to improve patients’ lives.
R&D Strategy
- Rapid value creation through unique relationship with Russian pharmaceutical company and corresponding access to Russian and CIS markets
- Build portfolio of partnered and proprietary biopharmaceutical products
- Strategic Focus on G-Protein Coupled Receptors (GPCR) Targets using proprietary CBASTM technology platform
- Build competitive capabilities:
- Industrialize CBASTM, extend library size and library technologies
- Remain at the forefront of Innovative Monoclonal AntibodyTechnology
- Bispecific formats, enhanced mode of action
